FDA Approves Merck's Keytruda for Some Carcinoma Patients

Date : 11/09/2018 @ 10:13PM
Source : Dow Jones News
Stock : Merck & Company (New) (MRK)
Quote : 78.88  0.16 (0.20%) @ 11:16PM

FDA Approves Merck's Keytruda for Some Carcinoma Patients

Merck (NYSE:MRK)
Historical Stock Chart

1 Year : From May 2018 to May 2019

Click Here for more Merck Charts.
   By Stephen Nakrosis 

Merck & Co. Inc (MRK) said Friday the U.S. Food and Drug Administration approved the use of Keytruda in some patients suffering with hepatocellular carcinoma.

Hepatocellular carcinoma is a disease of the liver, usually seen in patients with chronic liver disease and cirrhosis.

"The approval of Keytruda for advanced hepatocellular carcinoma marks the second FDA approval for hepatocellular carcinoma in Merck's oncology portfolio this year," said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

The company said continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The latest approval marks the 14th indication for Keytruda.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

November 09, 2018 16:58 ET (21:58 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.